DOI : 10.1055/s-00000059

Pneumologie

Issue S 01 · Volume 73 · March 2019 DOI: 10.1055/s-009-42542


60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.
München, 13.–16.03.2019

Kongresspräsident: Prof. Dr. med. Jürgen Behr, München
Abstracts (HTML) List of Authors
  • P296
    Schulze, J; Smith, HJ; Eichhorn, C; Salzmann-Manrique, E; Dreßler, M; Zielen, S:

    Zusammenhang von Spirometrie und Bodyplethysmographie während einer Belastung induzierten bronchialen Obstruktion

  • P327
    Beck, E; Kaplan, A; Fitzgerald, JM; Azzi, GE; Engel, M; Buhl, R:

    Tiotropium provides greater improvements in FEV1 than leukotriene receptor antagonists as add-on to ICS in adults with asthma: a systematic review

  • P400
    Schultz, K; Wittmann, M; Wagner, R; Lehbert, N; Szentes, B; Schwarzkopf, L; Nowak, D; Faller, H; Schuler, M:

    Absolute Eosinophilenzahl und klinischer Verlauf von 333 konsekutiven Rehabilitanden mit nicht kontrolliertem Asthma

  • P492
    Munro, A; Vos, W; Mignot, B; Müllinger, B:

    Evaluierung von Lungendepositionsmustern für ICS mit verschiedenen Inhalationsgeräten in Patienten mit schwerem Asthma mittels eines In-Silico-Depositions-Modells

  • P524
    Mailänder, C:

    Omalizumab Selbstapplikation – Umfrage bei Ärzten und Patienten

  • P601
    Svedsater, H; Bosanquet, N; Jacques, L; Jones, R; LayFlurrie, J; Leather, DA; Vestbo, J; Woodcock, A:

    Effects of Fluticasone furoate/Vilanterol (FF/VI) on Patient Reported Outcomes (PRO): The Salford Lung Study in Asthma (SLS Asthma)

  • P664
    OʼByrne, P; Fitzgerald, JM; Bateman, E; Barnes, PJ; Zhong, N; Gustafson, P; Lamarca, R; Puu, M; Keen, C; Wang, M; Reddel, HK:

    Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma

  • P714
    Marth, K; Renner, A; Patocka, K; Pohl, W:

    Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria

  • P254
    Zangrilli, JG; Maspero, J; Harrison, T; Werkstrom, V; Wu, Y:

    Clinical Efficacy of Benralizumab in Patients with Severe, Uncontrolled Eosinophilic Asthma and Nasal Polyposis: Pooled Analysis of the SIROCCO and CALIMA Trials

  • P261
    Buhl, R; Heaney, L; Loefroth, E; Larbig, M; Konstantinos, K; Corti, V; Cao, H:

    Disease control and treatment pathways of asthma patients after initiating ICS/LABA

  • P262
    Beck, E; Fitzgerald, JM; Buhl, R; Casale, TB; Azzi, GE; Engel, M; Sigmund, R; Halpin, DMG:

    Tiotropium Respimat reduces episodes of asthma worsening in PrimoTinA-asthma, irrespective of baseline characteristics or season

  • P464
    Müllinger, B; Kolb, T; Gessler, T:

    Inhalationsgeräte mit kontrollierter Inhalation verbessern patientenrelevante Behandlungsergebnisse

  • P530
    Wiener, S; Wegner, S; Ernst, C:

    Cost Analysis of FeNO-based Asthma Management in Primary Care in Germany

  • P558
    Adamek, L; Plate, T; Shavit, A; Kanniess, F; Beier, J:

    DescRiption and charactErisation of asthmatiCs eligible for biolOGic therapy referral amoNg prImary and secondary care SEttings in Europe (RECOGNISE) study design, German part

  • P236
    Zangrilli, JG; Kamboj, A; Newbold, P; Hirsch, I:

    Characteristics of Patients With and Without Allergic Disease From Benralizumab Phase III Severe Asthma Trials